Technology Che News Today

University of Rochester's student newspaper, serving the University of Rochester community since 1873.

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of...

The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc.  today announced the U.S. Food and Drug Administration has approved INGREZZA® capsules for the treatment of adults with...

The Huntington Study Group together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease , today shares that the Phase 3...

Critical Path Institute (C-Path) and the Center for Health + Technology (CHeT) at University of Rochester today announced the release of two seminal publications about digital health technologies for Parkinson's.

/PRNewswire/ -- Critical Path Institute (C-Path) and the Center for Health + Technology (CHeT) at University of Rochester today announced the release of two...

- Statistically Significant Improvement in Chorea Associated with Huntingtons Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically...

Researchers at the University of Rochester Medical Centre describe how the data generated by smart wearables could potentially mean new treatments for Parkinson’s, which could have significant benefits for those in the early stage of the disease.

Smartwatches and phones have the potential to detect and measure severity and progression of important symptoms of Parkinson’s disease.